2-OHE1 Test · Dried Urine

Your body does not just make estrogen. It also breaks it down, and the routes it takes when doing so can shape your long-term risk for hormone-related conditions. 2-OHE1 (2-hydroxyestrone) is one of the main products of that breakdown, and measuring it gives you a glimpse into which path your body is favoring.

This is a research-stage marker without universal clinical cutpoints, so a single number will not give you a diagnosis. But tracking it alongside its sister metabolite, 16-alpha-hydroxyestrone, can offer early insight into estrogen processing that a standard hormone panel simply does not provide.

What 2-OHE1 Actually Reflects

When your liver processes estrone (one of the three main estrogens in your body), it can send it down one of several chemical pathways. The 2-hydroxylation pathway produces 2-OHE1, a molecule that has weak estrogen activity and, in some research contexts, appears to behave more like an anti-estrogen than a growth signal. The competing 16-alpha pathway produces a metabolite that retains stronger estrogenic effects.

Researchers often look at the balance between these two routes, expressed as the 2-OHE1 to 16-alpha-OHE1 ratio. A higher ratio means more of your estrogen is being shunted down the less proliferative pathway. That balance is influenced by liver enzymes (CYP1A1, CYP1A2, and CYP1B1, which help process drugs and hormones), your genetics, your body composition, and your diet.

Breast Cancer Associations

This is the most studied area, and the findings are genuinely mixed. Several large studies have failed to show a clear link between 2-OHE1 levels (or the 2-to-16 ratio) and overall breast cancer risk in postmenopausal women. But the picture changes when you look more carefully at subgroups and metabolic patterns.

What this means for you: 2-OHE1 is not a clean "good number, bad number" marker. It is a phenotype indicator that tells you which estrogen-processing route your body favors. Different phenotypes appear to carry different risks for different cancers and across different life stages, which is why two well-designed studies can reach opposing conclusions. Interpret it as one piece of a larger hormonal picture, not as a verdict.

After a Breast Cancer Diagnosis

In women already diagnosed with breast cancer, a higher urinary 2-OHE1 to 16-OHE1 ratio measured after diagnosis was associated with lower all-cause mortality over long-term follow-up. The signal here is more consistent than for risk before diagnosis, suggesting the marker may carry prognostic information once disease is present.

Prostate Cancer Risk in Men

2-OHE1 is not just a women's marker. In a pooled analysis of prostate cancer cases and controls, men in the highest third of the 2-OHE1 to 16-alpha-OHE1 ratio had roughly half the odds of prostate cancer compared with men in the lowest third (pooled odds ratio around 0.53). Higher 16-alpha-OHE1 on its own was linked to higher odds of prostate cancer. The 2-OHE1 level alone, however, did not reach statistical significance.

Metabolic Health and Body Composition

Here the story flips in a way worth understanding. In premenopausal women, urinary 2-OHE1 rises with BMI and is positively correlated with fasting insulin, triglycerides, and total and LDL cholesterol, and inversely correlated with HDL. So while higher 2-OHE1 may be favorable in a cancer-risk context, accumulation in the setting of obesity tracks with adverse metabolic markers. Higher is not always better. The clinical meaning depends on the rest of your metabolic picture.

Bone Health

In a study of postmenopausal women, those with lower 2-OHE1 to 16-alpha-OHE1 ratios had less bone loss. The interpretation is that faster shunting of estrogen toward the inactive 2-pathway leaves less biologically active estrogen available for bone preservation. This is a useful reminder that the same metabolic shift carries different consequences for different tissues.

Resolving the Contradictions

If 2-OHE1 looks protective for premenopausal breast cancer and prostate cancer but neutral or even harmful in other contexts, what is going on? The simplest framework: this is not a marker where a single direction maps to better health. It reflects how your liver routes estrogen, and the consequences of that routing differ by tissue, sex, menopausal status, and overall hormone exposure. A high 2-OHE1 in a lean premenopausal woman with healthy lipids likely means something very different than the same number in a woman with obesity and insulin resistance. Read it in context, not in isolation.

Other Conditions Where 2-OHE1 Shifts

• Endometriosis: women with endometriosis show higher urinary 2-OHE1 than controls, and the 2-hydroxylation pathway appears enriched, particularly in ovarian endometriosis.
• Cirrhosis: 2-OHE1 drops sharply with a relative rise in 16-alpha-OHE1, part of the abnormal estrogen pattern underlying the feminizing signs of advanced liver disease.
• Preeclampsia: circulating 2-hydroxyestrone is lower than in healthy pregnancies, part of broader estrogen-metabolism disruption linked to vascular dysfunction.
• Endometrial cancer: the 2-OHE1 to 16-alpha-OHE1 ratio did not show protection in postmenopausal women, suggesting the favorable cancer signal seen elsewhere does not extend here.

Reference Ranges

There are no standardized clinical cutpoints for 2-OHE1. The values below come from a case-control study and serve only as orientation for what tertile boundaries look like in one cohort. They are not universal targets, and your lab will likely report different numbers using different units, assay methods, and specimen types.

Source: Barba et al. 2009, urinary measurement in male controls in a Western New York cohort. Compare your results within the same lab over time, not against absolute thresholds from a different population.

Why One Reading Is Not Enough

Estrogen metabolism shifts with menstrual cycle phase, body composition, diet, alcohol use, contraceptive use, hormone therapy, and even ethnicity. A single 2-OHE1 measurement captures a moment, not a pattern. For premenopausal women, sampling at the same cycle phase across measurements is essential. For everyone, the meaningful signal is the trajectory: does your ratio shift after dietary changes, weight changes, or starting hormone therapy?

A reasonable cadence: establish a baseline, retest in 3 to 6 months if you have changed your diet, body composition, or hormone exposure, and at least annually thereafter to track drift.

When Results Can Be Misleading

A few factors can distort a single reading and lead you to the wrong conclusion:

• Assay method: older enzyme immunoassays (lab tests that use antibodies to measure hormone levels) are less reliable than mass spectrometry, especially at the low concentrations typical in postmenopausal women. If your lab uses an immunoassay, very low results carry more uncertainty.
• Menstrual cycle timing: in premenopausal women, estrogen metabolite levels shift across the cycle. Comparing two samples drawn at different phases can produce misleading differences.
• Oral contraceptives: ethinyl estradiol with drospirenone increases hydroxylation and methylation of endogenous estrogens, including a rise in 2-OHE1, without indicating a change in your underlying disease risk.
• Pregnancy: urinary 2-OHE1 declines early and stays low, reflecting a normal physiologic shift, not pathology.

What an Abnormal Result Should Prompt

Because 2-OHE1 is a research-stage marker without standardized cutpoints, an unusual result is a flag for further investigation rather than a diagnosis. A low ratio in a postmenopausal woman with other estrogen-driven risk factors (family history of breast cancer, prior hormone therapy use, obesity) is worth discussing with a clinician who works with hormone metabolism, often a gynecologist with endocrine interest or a preventive medicine specialist. Pair the result with a full estrogen panel (estradiol, estrone, estriol), SHBG, and ideally the full DUTCH-style metabolite breakdown. For men with a low 2-to-16 ratio plus other prostate risk factors, an updated PSA and a prostate workup may be appropriate.

The pattern that warrants action is rarely 2-OHE1 alone. It is 2-OHE1 alongside other markers that tell a consistent story about how estrogen is being made, processed, and cleared.